⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
TGTX News
TG Therapeutics, Inc.
Form 8-K
sec.gov
TGTX
TG Therapeutics Announces Positive Topline Phase 1 Data for Subcutaneous BRIUMVI in Patients with Myasthenia Gravis and Initiation of Potential Registration Directed Randomized Phase 2 Trial
globenewswire.com
TGTX
Form 8-K
sec.gov
TGTX
TG Therapeutics Announces Positive Results from Phase 1 Trial Evaluating Subcutaneous BRIUMVI® (ublituximab-xiiy)
globenewswire.com
TGTX
TG Therapeutics to Participate in the Goldman Sachs 47th Annual Healthcare Conference
globenewswire.com
TGTX
TG Therapeutics Announces Publication of Post-Hoc Data from the Phase 3 ULTIMATE I & II Trials in Treatment Naive Patients with Relapsing Forms of MS Published in Frontiers in Immunology
globenewswire.com
TGTX
TG Therapeutics to Participate in the Jefferies Global Healthcare Conference
globenewswire.com
TGTX
Form 8-K
sec.gov
TGTX
TG Therapeutics Announces Positive Topline Results from Phase 3 ENHANCE Trial
globenewswire.com
TGTX
TG Therapeutics Announces Data Presentations for BRIUMVI® at the 2026 Consortium of Multiple Sclerosis Centers Annual Meeting
globenewswire.com
TGTX